Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Long-Term Deferred Tax (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Long-Term Deferred Tax for 15 consecutive years, with $24.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Deferred Tax rose 43.6% to $24.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $24.2 million, a 43.6% increase, with the full-year FY2024 number at $19.6 million, up 47.88% from a year prior.
  • Long-Term Deferred Tax was $24.2 million for Q3 2025 at Usana Health Sciences, down from $26.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $26.4 million in Q2 2025 to a low of $4.5 million in Q2 2022.
  • A 5-year average of $12.6 million and a median of $12.2 million in 2022 define the central range for Long-Term Deferred Tax.
  • Biggest YoY gain for Long-Term Deferred Tax was 138.23% in 2022; the steepest drop was 12.04% in 2022.
  • Usana Health Sciences' Long-Term Deferred Tax stood at $5.5 million in 2021, then surged by 79.3% to $9.8 million in 2022, then skyrocketed by 35.56% to $13.3 million in 2023, then soared by 47.88% to $19.6 million in 2024, then rose by 22.97% to $24.2 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Long-Term Deferred Tax are $24.2 million (Q3 2025), $26.4 million (Q2 2025), and $18.8 million (Q1 2025).